NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,273 | -64.4% | 6,892 | -8.3% | 0.00% | -100.0% |
| Q2 2023 | $312,290 | -34.4% | 7,519 | -4.6% | 0.00% | 0.0% |
| Q1 2023 | $476,208 | -30.4% | 7,878 | -15.6% | 0.00% | 0.0% |
| Q4 2022 | $684,088 | -12.3% | 9,334 | -9.1% | 0.00% | -50.0% |
| Q3 2022 | $780,000 | -3.3% | 10,263 | -11.5% | 0.00% | 0.0% |
| Q2 2022 | $807,000 | -14.0% | 11,591 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $938,000 | +13.6% | 11,626 | +6.0% | 0.00% | 0.0% |
| Q4 2021 | $826,000 | -20.3% | 10,972 | +22.9% | 0.00% | 0.0% |
| Q3 2021 | $1,036,000 | -75.1% | 8,930 | -52.8% | 0.00% | -77.8% |
| Q2 2021 | $4,162,000 | +237.8% | 18,910 | +103.0% | 0.01% | +200.0% |
| Q1 2021 | $1,232,000 | -62.5% | 9,313 | -50.9% | 0.00% | -66.7% |
| Q4 2020 | $3,283,000 | +29.4% | 18,978 | -18.5% | 0.01% | +12.5% |
| Q3 2020 | $2,538,000 | +330.2% | 23,282 | +134.5% | 0.01% | +300.0% |
| Q2 2020 | $590,000 | -74.6% | 9,929 | -82.0% | 0.00% | -80.0% |
| Q1 2020 | $2,327,000 | – | 55,028 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |